The inhibition of phosphatases by adenosine 5′-phosphorothioate (AMPS) was first reported in the late 1960s; however, the structural basis for the inhibition has remained unknown. Here, it is shown that AMPS is a submicromolar inhibitor of class C acid phosphatases, a group of bacterial outer membrane enzymes belonging to the haloacid dehalogenase structural superfamily. Furthermore, the 1.35-Å resolution crystal structure of the inhibited recombinant *Haemophilus influenzae* class C acid phosphatase was determined; this is the first structure of a phosphatase complexed with AMPS. The conformation of AMPS is identical to that of the substrate 5′-AMP, except that steric factors force a rotation of the thiophosphoryl out of the normal phosphoryl-binding pocket. This conformation is catalytically nonproductive, because the P atom is not positioned optimally for nucleophilic attack by Asp64, and the O atom of the scissile O–P bond is too far from the Asp (Asp66) that protonates the leaving group. The structure of 5′-AMP complexed with the Asp64→Asn mutant enzyme was also determined at 1.35-Å resolution. This mutation induces the substrate to adopt the same nonproductive binding mode that is observed in the AMPS complex. In this case, electrostatic considerations, rather than steric factors, underlie the movement of the phosphoryl. The structures not only provide an explanation for the inhibition by AMPS, but also highlight the precise steric and electrostatic requirements of phosphoryl recognition by class C acid phosphatases. Moreover, the structure of the Asp64→Asn mutant illustrates how a seemingly innocuous mutation can cause an unexpected structural change.

Database
Coordinates and structure factor amplitudes are available in the Protein Data Bank database under the accession numbers 3OCZ (rP4–AMPS) and 3SF0 (rP4 D64N–5′-AMP).

Introduction
Class C acid phosphatases (CCAPs, EC 3.1.3.2) constitute a large group of bacterial enzymes related by several shared characteristics. Conserved features of CCAPs include a 25-residue bipartite sequence motif featuring four essential Asp residues [1], a subunit molecular mass of approximately 30 kDa, and subcellular localization

Abbreviations
AMPS, adenosine 5′-phosphorothioate; CCAP, class C acid phosphatase; FtCCAP, *Francisella tularensis* class C acid phosphatase; HAD, haloacid dehalogenase; mdN, human mitochondrial deoxyribonucleotidase; NR, nicotinamide riboside; P4, *Haemophilus influenzae* class C acid phosphatase; PDB, Protein Data Bank; pNPP, p-nitrophenyl phosphate; rP4, recombinant *Haemophilus influenzae* class C acid phosphatase.
to the bacterial outer membrane. Structural and biophysical studies have shown that CCAPs have the halo-acid dehalogenase (HAD) fold and are dimeric in solution [2–4]. Kinetic studies of several CCAPs indicate a substrate preference for NMPs, which has led to the classification of CCAPs as broad-specificity 5',3'-nucleotidases [3,5–10].

Although the defining characteristics of the family are established, the biological functions of CCAPs are less certain. The Haemophilus influenzae class C acid phosphatase (P4) is the best-studied member of the CCAP family. Kemmer et al. showed that one function of P4 is to dephosphorylate NMN to nicotinamide riboside (NR) as part of a vestigial NAD⁺ utilization pathway [11]. Whether other CCAPs also function in NAD⁺ utilization is unknown.

High-resolution crystal structures of recombinant P4 (rP4) complexed with substrates have provided insights into the nucleotidase activity of CCAPs [12]. Structures of a substrate-trapping mutant rP4 complexed with NMN, 5'-AMP, 3'-AMP and 2'-AMP were determined. The structures revealed that the base binds in an aromatic box such that the hydrogen-bonding groups do not contact the protein. This result is consistent with the general lack of base specificity of rP4 and other CCAPs. The region around the ribose is relatively open, allowing recognition of both 5'-substrates and 3'-substrates. The phosphoryl is tightly surrounded by numerous charged and polar groups. This crowded environment is necessary for positioning the phosphoryl for nucleophilic attack by Asp64 and protonation of the leaving group by Asp66. Importantly, the span between the phosphoryl pocket and the aromatic box is optimal for binding NMPs, which is consistent with the classification of CCAPs as 5',3'-nucleotidases. Given the high sequence identity of the active sites of CCAPs, these features of substrate recognition are expected to be valid for the entire family.

The observation that the rP4 active site is well suited for binding NMP substrates motivated us to investigate the inhibition of CCAPs by the nucleotide analog adenosine 5'-phosphorothioate (AMPS, also called adenosine 5'-O-thiomonophosphate) (Scheme 1). AMPS differs from 5'-AMP by the substitution of an S atom for one of the O atoms of the phosphoryl, and is thus isostructural with 5'-AMP. AMPS has been shown to be a competitive inhibitor or very poor substrate of 5'-nucleotidases [13,14], but the structural basis of the inhibition is not known. We show here that AMPS is also an inhibitor of CCAPs, and provide a structural explanation for the observed inhibition.

### Results

#### Inhibition kinetics

AMPS was tested as an inhibitor of CCAPs by using rP4 (UniProtKB C9MJZ6) and the CCAP from Francisella tularensis (FtCCAP, UniProtKB Q5NH51). The two enzymes share only 20% global (26% local) amino acid sequence identity, and thus represent two distant branches of the CCAP family. Double reciprocal plots suggested that the inhibition mechanism for both enzymes is competitive, which is expected for an AMP analog. The inhibition constant ($K_i$) was estimated by using global fitting to the competitive model [Eqn (1) in Experimental procedures]. The fits were satisfactory ($R^2$ of 0.97 for rP4 and 0.99 for FtCCAP) and yielded $K_i$ values of 0.03 μM for rP4 and 0.3 μM for FtCCAP (Table 1). Thus, AMPS is a submicromolar inhibitor of these two CCAPs.

#### Structure of rP4 inhibited by AMPS

The crystal structure of rP4 complexed with AMPS was determined at 1.35-Å resolution (Table 2). AMPS binds in the previously identified substrate-binding site, which is located at the junction between the core and cap domains (Fig. 1). The adenine base interacts exclusively with the cap domain, whereas the thiophosphoryl interacts with the core domain. The binding of AMPS to the substrate site is consistent with AMPS being a competitive inhibitor.

The electron density at 1.35-Å resolution allowed for unequivocal determination of the inhibitor conformation, as well as the conformations of surrounding side chains and positions of active site water molecules.
Inhibition of CCAPs by AMPS

---

**Table 1.** Inhibition of CCAPs by AMPS with pNPP as the substrate.

<table>
<thead>
<tr>
<th>CCAP</th>
<th>$K_i$ (mM)</th>
<th>$k_{cat}$ (s$^{-1}$)</th>
<th>$K_i$ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rP4</td>
<td>0.12 ± 0.02</td>
<td>3.3 ± 0.1</td>
<td>0.035 ± 0.006</td>
</tr>
<tr>
<td>F1CCAP</td>
<td>0.56 ± 0.04</td>
<td>0.17 ± 0.01</td>
<td>0.30 ± 0.03</td>
</tr>
</tbody>
</table>

---

The conformation of AMPS is identical to that of 5’-AMP bound to the D66N substrate-trapping mutant of rP4 [12], except that the thiophosphoryl is shifted by 1.2 Å from the phosphoryl of 5’-AMP (Fig. 3). In both structures, the adenine base binds in an aromatic box formed by Phe86, Trp91, and Tyr221, and the ribose interacts with Glu131 via a water-mediated hydrogen bond. The shift of the thiophosphoryl reflects an apparent rotation of $\sim 20^\circ$ around the C4’–C5’ bond.

The 20° rotation around the C4’–C5’ bond of AMPS is significant, because it moves the thiophosphoryl away from two essential catalytic residues, Asp64 and Asp66. The former functions as the nucleophile that protonates the substrate leaving group. The distance between the nucleophile and the P atom of AMPS is 3.3 Å, and the angle formed by the nucleophile, P, and O5’ is 137°. The corresponding values for 5’-AMP are 3.0 Å and 173°, which are more consistent with backside nucleophilic attack. The rotation also displaces the O atom of the scissile O–P bond beyond the reach of Asp66. The O5’–Asp66 distances are 3.4 Å and 2.8 Å for AMPS and 5’-AMP, respectively. These subtle changes in the positioning of the thiophosphoryl lock the inhibitor in a nonproductive binding mode.

The identity of the S atom of AMPS was deduced from anomalous difference Fourier analysis, in order to better understand the basis for the displacement of the thiophosphoryl. Although the anomalous signal for S is low at the wavelength of the data collection ($I''$ is 0.18 e$^{-}$ for P and 0.23 e$^{-}$ for S), the anomalous difference Fourier map was unambiguous. Peaks 1 and 5 of the map correspond to the P and S atoms of AMPS, respectively (magenta surface in Fig. 2). We note that peaks 2–4 and 6 correspond to S atoms of Met residues. The P–S bond points 180° away from the back wall of the active site. Consequently, the S atom sits in an open solvent-filled region of the active site and makes no direct contacts with the enzyme.

With the S atom identified, the interactions involving the O atoms of the thiophosphoryl are evident (Fig. 3). One of the O atoms interacts with the metal ion $\text{Mg}^{2+}$, and the other interacts with Lys161. Unlike the phosphoryl of 5’-AMP, the thiophosphoryl does not interact directly with conserved Thr124 or the backbone of Asp66. Instead, a water molecule mediates the interactions with these groups (denoted wat1 in Fig. 3).

Binding of AMPS does not disrupt the octahedral coordination geometry of the $\text{Mg}^{2+}$. In ligand-free rP4 [Protein Data Bank (PDB) code 3ET4], the metal ion

---

**Table 2.** Data collection and refinement statistics. Values for the outer resolution shell of data are given in parentheses. $R_{merge}$ was calculated with HKL2000; $R_{free}$ and $R_{free}$, were calculated with SCALA [28] after integration with XDS [29]. The Ramachandran plot was generated with RAMPAGE [31].

<table>
<thead>
<tr>
<th>Complex</th>
<th>Wavelength</th>
<th>Space group</th>
<th>Unit cell (Å)</th>
<th>Data collection</th>
<th>Resolution (Å)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rP4-AMPS</td>
<td>0.9792</td>
<td>P6$_2$$\bar{2}$2</td>
<td>a = 98.2, c = 107.0</td>
<td>50–1.35 (1.40–1.35)</td>
<td>50–1.35 (1.40–1.35)</td>
</tr>
<tr>
<td>rP4 D64N-5’-AMP</td>
<td>0.9795</td>
<td>P6$_2$$\bar{2}$2</td>
<td>a = 97.9, c = 107.0</td>
<td>50–1.35 (1.40–1.35)</td>
<td>50–1.35 (1.40–1.35)</td>
</tr>
</tbody>
</table>

---

$^a$ A common set of test reflections (5%) was used for refinement of all structures. $^b$ Compared with the parameters of Engh and Huber [30]. $^c$ Maximum likelihood-based coordinate error estimate.
bonds to Asp64, Asp181, the backbone carbonyl of Asp66, and three water molecules. One of the coordinating water molecules dissociates upon substrate binding, and an O atom of the phosphoryl takes its place. An analogous exchange occurs during the binding of AMPS.

**Fig. 1.** Ribbon representation of rP4 complexed with AMPS. The core and cap domains are colored blue and pink, respectively. AMPS is colored gray; the S atom of AMPS is colored magenta. The yellow sphere represents Mg$^{2+}$. This figure and the others were created with PYMOL [32].

**Fig. 2.** Electron density maps showing the presence of AMPS in the active site (relaxed stereographic view). The cage (cyan for the ligand; silver for protein side chains) represents a simulated annealing $\sigma_A$-weighted $F_o - F_c$ omit map contoured at 3.0$\sigma$. Prior to map calculation, the ligand and surrounding residues and water molecules were removed, and simulated annealing refinement was performed with PHENIX. The magenta surface represents an anomalous difference Fourier map contoured at 3.0$\sigma$. Note that this map exhibits peaks corresponding to the P and S atoms of the thiophosphoryl.

**Mutation of the Asp nucleophile induces the nonproductive conformation in the substrate**

The conformation of AMPS is reminiscent of substrates bound to human mitochondrial deoxyribonucleotidase (mdN) [16]. This enzyme also belongs to the HAD structural superfamily, but the cap domain fold and quaternary structure are substantially different from those of rP4. In order to trap NMP substrates bound to mdN, Walldén et al. mutated the essential nucleophile (Asp41) to Asn. The substrates bound with the phosphoryl in one or both of two alternative conformations, which were called mode A and mode B. Mode A is the active conformation and resembles 5'-AMP bound to the D66N mutant. Mode B is a nonproductive conformation and resembles AMPS. Presumably, the adoption of the mode B conformation results from the alteration of the electrostatic environment caused by the mutation of the negatively charged Asp41 to Asn.

Mutation of the Asp64 nucleophile in rP4 also induces the substrate to adopt the nonproductive mode B conformation. The structure of the D64N mutant complexed with 5'-AMP was determined at 1.35 Å resolution (Table 2). The electron density map definitively indicates only a single conformation, which is very similar to that of AMPS (Fig. 4). The only substantial difference between the two structures involves Lys161. In the AMPS complex, Lys161 interacts with Asp64, Asp185, and a thiophosphoryl O atom (Fig. 5, black dashes). In the rP4 D64N–5'-AMP complex, however, Lys161 has rotated 90° around the C$\delta$–C$\varepsilon$ bond to avoid an electrostatic clash with the side chain amine group of Asn64. This new conformation of Lys161 maintains the ion pair with Asp185 and also allows a new interaction with a different phosphoryl O.
**Fig. 3.** Active site of rP4 inhibited by AMPS (relaxed stereographic view). AMPS is colored white; the S atom of AMPS is colored magenta. For reference, 5'-AMP from the rP4 D66N-5'-AMP structure (PDB code 3OCV) is also shown (yellow). Secondary structural elements of the core and cap domains are colored blue and pink, respectively. The yellow sphere represents Mg$^{2+}$. The dashed lines denote electrostatic interactions in the AMPS complex.

**Fig. 4.** Electron density map showing the presence of 5'-AMP in the active site of rP4 D64N (relaxed stereographic view). The cage (cyan for the ligand, silver for protein side chains) represents a simulated annealing $\sigma_A$-weighted $F_o - F_c$ omit map contoured at 3.0$\sigma$. Prior to map calculation, the ligand and surrounding residues and water molecules were removed, and simulated annealing refinement was performed with PHENIX.

**Fig. 5.** Comparison of rP4-AMPS (gray with magenta S atom) and rP4 D64N-5'-AMP (cyan) (relaxed stereographic view). The black and cyan dashes denote electrostatic interactions in rP4-AMPS and rP4 D64N-5'-AMP, respectively. For reference, the 5'-AMP bound to rP4 D66N is shown in yellow. The yellow sphere represents Mg$^{2+}$. 

Inhibition of CCAPs by AMPS

H. Singh et al.

4378

atom (the O atom corresponding to the S atom of the thiophosphoryl; see Fig. 5, cyan dashes).

**Discussion**

Murray and Atkinson reported in 1968 that AMPS is a competitive inhibitor (K<sub>i</sub> value of 20 µM) of the type II 5'-nucleotidase from *Crotalus adamanteus* venom [13]. One plausible explanation for the inhibition is that the lower electronegativity of S than of O causes the P atom of AMPS to be less electrophilic than that of 5'-AMP and therefore less susceptible to nucleophilic attack by the enzyme. In this scenario, one might expect the inhibitor to adopt the same conformation as the substrate.

The rP4–AMPS structure suggests a different mechanism of inhibition based on steric considerations. The larger size of S than of O prevents the thiophosphoryl from occupying the catalytically active conformation. The phosphoryl-binding site appears to be too congested, and apparently not flexible enough, to accommodate the larger S atom. This steric conundrum is solved by rotating the thiophosphoryl away from the back wall of the active site, which allows the S atom to protrude into an open solvent-filled cavity. As a consequence of the rotation, the P atom is not positioned optimally for nucleophilic attack by Asp64. Furthermore, the O atom of the scissile O–P bond is too far from the Asp (Asp66) that protonates the leaving group. Thus, AMPS is an inhibitor of rP4.

This nonproductive mode of binding is also adopted by substrates bound to rP4 D64N. In this case, electrostatic considerations underlie the rotation of the phosphoryl. Mutation of Asp to Asn decreases the negative charge of the active site and places an obligate hydrogen bond donor group next to Lys161. It appears that Lys161 rotates to avoid the electrostatic repulsion, and that this, in turn, induces rotation of the phosphoryl into the mode B position. Taken together, the two rP4 structures reported here highlight the precise steric and electrostatic requirements of phosphoryl recognition by rP4.

We note that a similar rotation of the phosphoryl was not observed for rP4 D66N. Asp66 functions as the acid that protonates the leaving group, and is therefore protonated at the beginning of the catalytic cycle. Thus, mutation of Asp66 to Asn does not change the overall charge of the active site. For this reason, rP4 D66N is superior to rP4 D64N as a substrate-trapping enzyme.

The rP4 D64N structure also illustrates the potential pitfalls of the common practice of using active site mutants to understand enzyme structure and mechanism. Most biochemists consider the mutation of Asp to Asn to be a conservative change. Nevertheless, this mutation at residue 64 of rP4 induced the substrate to adopt a conformation that does not reflect the conformation of the substrate bound to the native enzyme. Interestingly, this artefact was avoided in rP4 by mutating Asp66 rather than Asp64. These results remind us that seemingly innocuous mutations can induce unexpected structural changes, depending on the three-dimensional context of the mutated residue.

The data reported here could potentially aid inhibitor design efforts. For example, it has been suggested that targeting the NAD<sup>+</sup> utilization pathway may be a possible route to the development of narrow-spectrum antimicrobial agents against *H. influenzae* [17]. The NAD<sup>+</sup> utilization pathway of *H. influenzae* includes an uptake system that imports NAD<sup>+</sup>, NMN and NR into the periplasm. The periplasmic NAD<sup>+</sup> nucleotidase NadN catalyzes the hydrolysis of NAD<sup>+</sup> to generate NMN and AMP. NMN is dephosphorylated in the periplasm by P4 to NR, which is transported across the inner membrane into the cytosol by the NR-specific permease PnuC. Finally, the bifunctional NR kinase/NMN adenylyltransferase NadR converts NR into NAD<sup>+</sup>. All of these enzymes and transporters are potential targets for inhibitor design. The structural and kinetic data reported here provide a potential starting point for the design of specific inhibitors of P4.

The similarities between the nonproductive nucleotide conformations reported here for rP4 and observed previously for mdN may provide new insights for the design of inhibitors of human 5'-nucleotidases. 5'-Nucleotidases regulate the nucleotide pool by reversing the action of nucleoside kinases [18]. They have been implicated in decreasing the efficacy of antiviral and antiblastic nucleoside analogs. Phosphorylation in vivo activates these drugs. As intracellular 5'-nucleotidases can reverse this activation step, they decrease drug efficacy. For this reason, designing inhibitors of 5'-nucleotidases for cotherapy is of interest. P4 and mdN share a similar core domain that includes the essential DDDD motif and a hydrophobic region for binding the nucleotide base. The occurrence of the mode B substrate conformation in structures of rP4 D64N and mdN D41N attests to the similarities of their phosphoryl-binding pockets. These observations raise the possibility that AMPS could be an inhibitor of mdN.

**Experimental procedures**

**Kinetics of inhibition**

His-tagged rP4 and FtCCAP were expressed and purified as described previously [12,19]. AMPS was purchased from
Sigma-Aldrich (St Louis, MO, USA) (catalogue number A1640). Steady-state enzymatic activity was assessed at 25 °C with p-nitrophenyl phosphate (pNPP) as the substrate and with a discontinuous assay that measures the production of p-nitrophenolate [20,21]. The assay buffer consisted of 0.2 M sodium acetate and 1 mM MgCl₂ (pH 5.5). The substrate concentration was varied in the range 0.1–5 mM at fixed AMPS concentrations of 0.25–1.0 μM. The reaction was stopped with 1.0 mM glycine (pH 10) after reaction times of 15, 75, 135, and 195 s. The p-nitrophenolate concentration was determined spectrophotometrically at 405 nm by reference to a standard curve constructed from solutions of known p-nitrophenolate concentration. The initial rate was estimated by fitting data from the four time points to a line. The kinetic parameters for pNPP (V_{max}, K_m) and K_i for AMPS were estimated by global fitting to the competitive inhibition model with ORIGIN 8.5.

\[ v = \frac{V_{max}[S]}{K_m(1 + [I]/K_i)} + [S] \]  

(1)

**Preparation of rP4–AMPS and rP4 D64N–5′-AMP crystals**

His-tagged rP4 was expressed from a pET20b plasmid and purified as described previously [12]. A site-directed mutant of rP4 in which Asp64 is changed to Asn (rP4 D64N) was created by overlap extension PCR from the pET20b plasmid containing the rP4 coding sequence. The mutation was verified by DNA sequencing, and the mutated plasmid was transformed into BL21(AI) for large-scale protein expression with Studier’s autoinduction method [22]. His-tagged rP4 D64N was purified as described previously for rP4 [12].

Hexagonal crystals of rP4 and rP4 D64N were grown as described previously for rP4 and rP4 D66N [12]. The crystals were grown in sitting drops (1 μL of protein and 1 μL of reservoir) at room temperature over reservoirs containing 0.05–0.2 M ammonium citrate, 0.05–0.15 mM MgCl₂, and 18–23% (w/v) poly(ethylene glycol) 3350 in the pH range 6.8–7.2.

Crystals of enzyme–ligand complexes were obtained by soaking. Crystals of rP4 were first cryoprotected at room temperature in 23–28% (w/v) poly(ethylene glycol) 3350, 0.1 M ammonium citrate buffer (pH 7.0), and 20% poly(ethylene glycol) 200. The cryoprotected crystals were transferred to a solution of the cryobuffer supplemented with 200 mM MgCl₂ and 10–15 mM AMPS. After 15–35 min, the crystals were picked up with Hampton loops and plunged into liquid nitrogen. Crystals of rP4 D64N complexed with 5′-AMP were prepared similarly, except that the substrate concentration was 10–23 mM, the MgCl₂ concentration was 100 mM, and the soaking times were 30–75 min.

**Structure determination**

X-ray diffraction data were collected at the Advanced Photon Source beamline 24-ID-C and processed with HKL2000 [23] (Table 1). The crystals have space group P6_322 with unit cell lengths of a = 98 Å and c = 107 Å, and there is one molecule in the asymmetric unit with 54% solvent content and V_m of 2.6 Å³/Da [24,25]. We note that this crystal form is the same one used to determine structures of rP4 D66N complexed with substrates [12]. PHENIX [26] and COOT [27] were used for structure refinement and model building, respectively. Refinement was initiated from a model derived from the coordinates of a 1.35-Å resolution structure of rP4 (PDB code 3OCU). The test set of reflections (5%) was based on that used for previous refinements of rP4 structures [12]. The B-factor model used during the initial rounds of refinement consisted of an isotropic B-factor for each nonhydrogen atom and TLS refinement (one TLS group for the entire protein chain). During the final few rounds of refinement, anisotropic B-factors were used, which decreased R_free by 0.016 for the AMPS structure (0.175–0.159) and by 0.023 for the rP4 D64N structure (0.185–0.162).

**Acknowledgements**

H. Singh was supported by a pre-doctoral fellowship from National Institutes of Health grant DK071510 and a Chancellor’s Dissertation Completion Fellowship from the University of Missouri-Columbia. We thank J. Schuermann for help with X-ray data collection. Part of this work is based upon research conducted at the Northeastern Collaborative Access Team beamlines of the Advanced Photon Source, supported by award RR-15301 from the National Center for Research Resources at the National Institute of Health. Use of the Advanced Photon Source is supported by the US Department of Energy, Office of Basic Energy Sciences, under contract No. W-31-109-ENG-38.

**References**

4. Singh H, Malinski TJ, Reilly TJ, Henzl MT & Tanner JJ (2011) Crystal structure and immunogenicity of the...


Inhibition of CCAPs by AMPS